Anbio Biotechnology SEC filings NNNN
Anbio Biotechnology has 43 filings in SEC EDGAR's recent list, going back to Dec 27, 2023. Its latest annual report, Form 20-F, was filed on Apr 7, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on May 19, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-3ASR | Automatic shelf registration statement of securities of well-known seasoned issu | Jul 9, 2026 | — |
| 6-K | Current report (foreign issuer) | May 19, 2026 | May 19, 2026 |
| 6-K | Current report (foreign issuer) | Apr 27, 2026 | Apr 27, 2026 |
| 20-F/A | Amended annual report (foreign issuer) | Apr 9, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Apr 7, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Feb 17, 2026 | Feb 17, 2026 |
| 6-K | Current report (foreign issuer) | Jan 26, 2026 | Jan 26, 2026 |
| 6-K | Current report (foreign issuer) | Dec 30, 2025 | Dec 30, 2025 |
| 6-K | Current report (foreign issuer) | Nov 13, 2025 | Nov 12, 2025 |
| 20-F | Annual report (foreign issuer) | Apr 28, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Feb 21, 2025 | Feb 21, 2025 |
| 424B4 | Prospectus | Feb 19, 2025 | — |
| EFFECT | Filing | Feb 18, 2025 | — |
| CERT | Filing | Feb 18, 2025 | — |
| CORRESP | Letter to the SEC | Feb 14, 2025 | — |
| CORRESP | Letter to the SEC | Feb 14, 2025 | — |
| 8-A12B | For registration of certain classes | Feb 14, 2025 | — |
| F-1/A | Registration statement | Feb 10, 2025 | — |
| F-1/A | Registration statement | Jan 24, 2025 | — |
| FWP | Free writing prospectus | Jan 22, 2025 | — |
| F-1/A | Registration statement | Jan 10, 2025 | — |
| F-1 | Registration statement (foreign issuer) | Dec 31, 2024 | — |
| DRSLTR | Filing | Dec 11, 2024 | — |
| DRS/A | Filing | Dec 11, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2024 | — |
| DRS/A | Filing | Nov 18, 2024 | — |
| DRSLTR | Filing | Jul 1, 2024 | — |
| DRS/A | Filing | Jul 1, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2024 | — |
| DRS/A | Filing | Jun 10, 2024 | — |
| DRSLTR | Filing | Jun 7, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 22, 2024 | — |
| DRS/A | Filing | Mar 11, 2024 | — |
| DRSLTR | Filing | Mar 8, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2024 | — |
| DRS | Filing | Dec 27, 2023 | — |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NNNN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Frankfurt Am Main, Germany
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1982708
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.